Xenetic Biosciences, Inc. financial data

Symbol
XBIO on Nasdaq
Location
945 Concord St., Framingham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 703 % -21%
Debt-to-equity 15.4 % +35.2%
Return On Equity -54.5 % -6.86%
Return On Assets -47.3 % -3.14%
Operating Margin -133 % +32.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.54M shares 0%
Common Stock, Shares, Outstanding 1.54M shares +0.07%
Entity Public Float 5.3M USD +5.47%
Common Stock, Value, Issued 1.55K USD +0.07%
Weighted Average Number of Shares Outstanding, Basic 1.54M shares +0.09%
Weighted Average Number of Shares Outstanding, Diluted 1.54M shares +0.09%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.45M USD -2.94%
Research and Development Expense 2.95M USD -24%
General and Administrative Expense 2.77M USD -24.3%
Operating Income (Loss) -3.27M USD +34.8%
Nonoperating Income (Expense) 182K USD -41.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -3.08M USD +34.4%
Earnings Per Share, Basic -2 USD/shares +34.9%
Earnings Per Share, Diluted -2 USD/shares +34.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 5.35M USD -33.2%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 5.35M USD -40.7%
Accounts Payable, Current 347K USD +22.3%
Employee-related Liabilities, Current 243K USD +12.4%
Accrued Liabilities, Current 611K USD +7.37%
Liabilities, Current 903K USD -43.1%
Liabilities 903K USD -43.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 254K USD 0%
Retained Earnings (Accumulated Deficit) -199M USD -1.58%
Stockholders' Equity Attributable to Parent 4.45M USD -40.2%
Liabilities and Equity 5.35M USD -40.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1M USD +13.6%
Common Stock, Shares Authorized 10M shares 0%
Common Stock, Shares, Issued 1.54M shares +0.07%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.78M USD -34.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 41.6M USD +2.97%
Deferred Tax Assets, Gross 41.1M USD +3.58%
Operating Lease, Liability, Current 0 USD -100%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 208M USD +0.04%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 16K USD -61.9%